Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other EventsItem 8.01 Other Events.
On February13, 2018, Synergy Pharmaceuticals Inc. issued a press release announcing that the Compensation Committee of the Board of Directors of Synergy approved the grant of inducement stock options to purchase 289,000 shares of Synergy common stock to 193 former contract sales representatives that have transitioned over to Synergy as part of its field force integration plan, with a grant date of February7, 2018. The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
99.1 |
Synergy Pharmaceuticals Inc. Press Release dated February13, 2018. |
SYNERGY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a18-6057_1ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK,…To view the full exhibit click here
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.